Drugs / Pentetreotide
Pentetreotide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00001849 | May 1999 → Apr 2019 | ectopic Cushing syndrome | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pentetreotide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001849 ↗ |
| Known as | (-)-pentetoreotide | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108757 ↗ |
| Known as | DTPA-SMS | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108757 ↗ |
| Known as | Pentetreotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108757 ↗ |
| Known as | SDZ 215-811 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108757 ↗ |
| Known as | SDZ 215-811S | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108757 ↗ |
| Modality | Diagnostic / imaging agent | “octreotide scan (octreoscan) using the conventional low dose of indium-111 pentetreotide.” NCT00001849 ↗ |